1. Home
  2. CRT vs MAIA Comparison

CRT vs MAIA Comparison

Compare CRT & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRT
  • MAIA
  • Stock Information
  • Founded
  • CRT 1991
  • MAIA 2018
  • Country
  • CRT United States
  • MAIA United States
  • Employees
  • CRT N/A
  • MAIA N/A
  • Industry
  • CRT Oil & Gas Production
  • MAIA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CRT Energy
  • MAIA Health Care
  • Exchange
  • CRT Nasdaq
  • MAIA Nasdaq
  • Market Cap
  • CRT 65.1M
  • MAIA 56.3M
  • IPO Year
  • CRT 1992
  • MAIA 2022
  • Fundamental
  • Price
  • CRT $7.70
  • MAIA $1.60
  • Analyst Decision
  • CRT
  • MAIA
  • Analyst Count
  • CRT 0
  • MAIA 0
  • Target Price
  • CRT N/A
  • MAIA N/A
  • AVG Volume (30 Days)
  • CRT 23.8K
  • MAIA 469.2K
  • Earning Date
  • CRT 01-01-0001
  • MAIA 11-11-2025
  • Dividend Yield
  • CRT 11.41%
  • MAIA N/A
  • EPS Growth
  • CRT N/A
  • MAIA N/A
  • EPS
  • CRT 0.92
  • MAIA N/A
  • Revenue
  • CRT $6,559,820.00
  • MAIA N/A
  • Revenue This Year
  • CRT N/A
  • MAIA N/A
  • Revenue Next Year
  • CRT N/A
  • MAIA N/A
  • P/E Ratio
  • CRT $8.40
  • MAIA N/A
  • Revenue Growth
  • CRT N/A
  • MAIA N/A
  • 52 Week Low
  • CRT $7.67
  • MAIA $1.40
  • 52 Week High
  • CRT $13.31
  • MAIA $3.48
  • Technical
  • Relative Strength Index (RSI)
  • CRT 22.97
  • MAIA 50.95
  • Support Level
  • CRT $8.46
  • MAIA $1.54
  • Resistance Level
  • CRT $7.87
  • MAIA $1.78
  • Average True Range (ATR)
  • CRT 0.17
  • MAIA 0.08
  • MACD
  • CRT -0.06
  • MAIA 0.01
  • Stochastic Oscillator
  • CRT 11.84
  • MAIA 46.53

About CRT Cross Timbers Royalty Trust

Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Share on Social Networks: